In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans
Authors:
- M. ObermeierMOM. Obermeier
- M. YaoMYM. Yao
- A. KhannaAKA. Khanna
- B. KoplowitzBKB. Koplowitz
- M. ZhuMZM. Zhu
- W. LiWLW. Li
- B. KomoroskiBKB. Komoroski
- S. KasichayanulaSKS. Kasichayanula
- L. DiscenzaLDL. Discenza
- W. WashburnWWW. Washburn
- W. MengWMW. Meng
- B. A. EllsworthBEB. A. Ellsworth
- 1 March 2010
- journal article
- clinical trial
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 38 (3) , 405-414
Abstract
(2S,3R,4R,5S,6R)-2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyl-tetrahydro-2H-pyran-3,4,5-triol (dapagliflozin; BMS-512148) is a potent sodium-glucose cotransporter type II inhibitor in animals and humans and is currently under development for the treatment of type 2 diabetes. The preclinical characterization of dapagliflozin, to allow compound selection and prediction of pharmacological and dispositional behavior in the clinic, involved Caco-2 cell permeability studies, cytochrome P450 (P450) inhibition and induction studies, P450 reaction phenotyping, metabolite identification in hepatocytes, and pharmacokinetics in rats, dogs, and monkeys. Dapagliflozin was found to have good permeability across Caco-2 cell membranes. It was found to be a substrate for P-glycoprotein (P-gp) but not a significant P-gp inhibitor. Dapagliflozin was not found to be an inhibitor or an inducer of human P450 enzymes. The in vitro metabolic profiles of dapagliflozin after incubation with hepatocytes from mice, rats, dogs, monkeys, and humans were qualitatively similar. Rat hepatocyte incubations showed the highest turnover, and dapagliflozin was most stable in human hepatocytes. Prominent in vitro metabolic pathways observed were glucuronidation, hydroxylation, and O-deethylation. Pharmacokinetic parameters for dapagliflozin in preclinical species revealed a compound with adequate oral exposure, clearance, and elimination half-life, consistent with the potential for single daily dosing in humans. The pharmacokinetics in humans after a single dose of 50 mg of [14C]dapagliflozin showed good exposure, low clearance, adequate half-life, and no metabolites with significant pharmacological activity or toxicological concern.Keywords
This publication has 27 references indexed in Scilit:
- Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2Bioorganic & Medicinal Chemistry Letters, 2008
- Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic RatsDiabetes, 2008
- Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABLCancer Chemotherapy and Pharmacology, 2007
- DPP-4 inhibitors and their potential role in the management of type 2 diabetesInternational Journal Of Clinical Practice, 2006
- Phlorizin: a reviewDiabetes/Metabolism Research and Reviews, 2004
- Chronic Hyperglycemia Triggers Loss of Pancreatic β Cell Differentiation in an Animal Model of DiabetesJournal of Biological Chemistry, 1999
- IMPORTANCE OF GLUCOSE CONTROLMedical Clinics of North America, 1998
- The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.Journal of Clinical Investigation, 1994
- Physiological Parameters in Laboratory Animals and HumansPharmaceutical Research, 1993
- Noncompartmental Analysis Based on Statistical Moment Theory1982